ValuEngine upgraded shares of Agilent Technologies (NYSE:A) from a hold rating to a buy rating in a research note released on Thursday, September 13th.
A has been the subject of several other research reports. Morgan Stanley lifted their price target on Agilent Technologies from $83.00 to $84.00 and gave the company an overweight rating in a research note on Wednesday, August 15th. Zacks Investment Research lowered Agilent Technologies from a buy rating to a hold rating in a research note on Wednesday, May 16th. Finally, Deutsche Bank boosted their price objective on Agilent Technologies from $77.00 to $80.00 and gave the stock a buy rating in a research note on Wednesday, August 15th. Ten research analysts have rated the stock with a buy rating, Agilent Technologies currently has an average rating of Buy and a consensus target price of $77.22.
Shares of Agilent Technologies stock traded down $0.36 on Thursday, hitting $70.30. The company’s stock had a trading volume of 2,376,806 shares, compared to its average volume of 2,526,579. The company has a quick ratio of 3.00, a current ratio of 3.62 and a debt-to-equity ratio of 0.39. Agilent Technologies has a 1 year low of $60.42 and a 1 year high of $75.00. The firm has a market cap of $22.49 billion, a PE ratio of 29.79, a P/E/G ratio of 2.42 and a beta of 1.32.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, August 14th. The medical research company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.04. Agilent Technologies had a return on equity of 18.61% and a net margin of 6.20%. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the previous year, the business earned $0.59 EPS. Agilent Technologies’s revenue for the quarter was up 8.0% compared to the same quarter last year. On average, sell-side analysts expect that Agilent Technologies will post 2.71 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 24th. Shareholders of record on Tuesday, October 2nd will be paid a dividend of $0.149 per share. The ex-dividend date is Monday, October 1st. This represents a $0.60 annualized dividend and a yield of 0.85%. Agilent Technologies’s dividend payout ratio (DPR) is currently 25.42%.
In other news, Director Paul N. Clark sold 2,876 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $68.60, for a total transaction of $197,293.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Heidi Fields sold 5,482 shares of the business’s stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $67.73, for a total value of $371,295.86. The disclosure for this sale can be found here.
Several institutional investors have recently modified their holdings of the company. SRS Capital Advisors Inc. lifted its holdings in Agilent Technologies by 75.9% in the second quarter. SRS Capital Advisors Inc. now owns 1,791 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 773 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its holdings in Agilent Technologies by 391.7% in the second quarter. Moneta Group Investment Advisors LLC now owns 6,023 shares of the medical research company’s stock valued at $158,000 after acquiring an additional 4,798 shares during the last quarter. Bray Capital Advisors lifted its holdings in Agilent Technologies by 12,000.0% in the second quarter. Bray Capital Advisors now owns 3,025 shares of the medical research company’s stock valued at $187,000 after acquiring an additional 3,000 shares during the last quarter. Point72 Asia Hong Kong Ltd lifted its holdings in Agilent Technologies by 303.2% in the first quarter. Point72 Asia Hong Kong Ltd now owns 2,859 shares of the medical research company’s stock valued at $191,000 after acquiring an additional 2,150 shares during the last quarter. Finally, Signaturefd LLC acquired a new position in Agilent Technologies in the first quarter valued at approximately $201,000.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.